Miralles Gines Diego

President & Head of R&D

Miralles Gines Diego has filed 3 SEC Form 4 filings (3 transaction rows) across 1 company, with disclosures dating back to 2026. 3 of those filings fall inside the rolling window. Most recent filing: Nov 18, 2026.

On the most recent filing, Miralles Gines Diego is listed as President & Head of R&D at Artiva Biotherapeutics, Inc. Inside the rolling window, Miralles Gines Diego reported no open-market purchases and 1 open-market sale totaling $4K in ARTV.

Companies traded

Other insiders at ARTV

Insider Buying

$0

reported purchases (SEC code P)

Insider Selling

$4K

reported sales (SEC code S)

Companies

1

in the rolling window

Source
ARTVSale$4KNov 18SEC ↗
Showing 1–1 of 1
1 / 1

Frequently asked questions

How many SEC Form 4 filings has Miralles Gines Diego made?

Miralles Gines Diego has filed 3 SEC Form 4 filings (3 transaction rows) across 1 company since 2026.

Which companies does Miralles Gines Diego trade?

Miralles Gines Diego has filed SEC Form 4 disclosures for 1 company, including ARTV.

When was Miralles Gines Diego's most recent SEC Form 4 filing?

Miralles Gines Diego's most recent SEC Form 4 filing on Tracefour is dated Nov 18, 2026.

What is Miralles Gines Diego's job title?

On the most recent SEC Form 4 filings tracked by Tracefour, Miralles Gines Diego is listed as President & Head of R&D.

What is Miralles Gines Diego's total buy and sell value in the current window?

Inside the rolling retention window, Miralles Gines Diego bought $0 and sold $4K based on SEC Form 4 filings.

What was Miralles Gines Diego's largest disclosed transaction?

The largest disclosed transaction in the current window is a sale of 1,043 ARTV shares on 2026-11-17, worth $4K, per SEC Form 4 filings.